at Investor's Business Daily (Mon, 6:42PM)
Mylan (MYL +0.9%) gets a boost today from an upgrade to Outperform at Leerink Swann, citing a better outlook for EpiPen sales and optimism over the company's 2013 guidance. The firm ups its price target to $30 from $26.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Nasdaq.com (Jan 21, 2015)
at Zacks.com (Jan 12, 2015)
at Zacks.com (Jan 9, 2015)
at Zacks.com (Jan 7, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs